Year: 2026
Type: article
Abstract: Recurrent gliomas, whether isocitrate dehydrogenase (IDH) mutant or wildtype, have limited effective treatments, supporting evaluation of biomarker-guided therapies. IDH mutations drive accumulation of 2-hydroxyglutarate, creating vulnerability within DNA damage response pathways by inducing homologous recombination deficiency (HRD). In preclinical models, HRD has been associated with sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition and appears reversible with IDH inhibition. Accurate characterisation of HRD in gliomas may inform its utility as a therapeutic biomarker.
Source: ESMO Open
Institutions: The Kinghorn Cancer Centre, UNSW Sydney
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7147087106
FWCI:
Cites:
Cited by:
Related to: